200 µg of LNCaP nuclear extract (Testosterone treated) at 4.04 µg/µl.
LNCaP nuclear extract (Testosterone treated) was prepared from cell cultures of the human prostate adenocarcinoma LNCaP cell line. The LNCaP cell line was originally derived from a supraclavicular lymph node metastatic lesion of a 50 year old Caucasian patient with metastatic prostate carcinoma. Prostate cancer is the second most common neoplasia in men. Because it is a hormone-responsive cancer, its treatment at initial stages of development typically involves anti-androgen adjuvant therapy. The fibroblast-like LNCaP cell line retains malignant properties that are characteristic of human prostate adenocarcinoma, including resistance to interferon, the expression of high levels of acid phosphatase, androgen receptors and Prostate Specific Antigen (PSA), and hormone responsiveness.
Treatment of LNCaP cells with testosterone and its biologically active metabolite dihydrotestosterone (DHT) stimulates cell growth and acid phosphatase production. The LNCaP cell line is most commonly used in research as a model for human prostate cancer.
LNCaP nuclear extract (Testosterone treated) is specifically recommended for studies related to prostate cancer.
Human epithelial prostate; metastatic site
LNCaP nuclear extract (Testosterone treated) is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT). Cells were cultured in medium supplemented with 10 nM Testosterone for 6 hours at 37°C immediately prior to harvesting.
Extracts have been quality control tested by Western blot and the Electrophoretic Mobility Shift Assay (EMSA).
To ensure stability, extracts should be stored at -80°C.
We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.
This product is guaranteed for 6 months from date of receipt.
This product is for research use only and is not for use in diagnostic procedures.